Diabetes, infection, lactic acidosis, and hepatic dysfunction were excluded.<h4>Management & outcome</h4>The SGLT2 inhibitor was discontinued, and the patient was treated with intravenous saline, insulin infusion, and dextrose. The gene discussed is SLC5A2; the disease is lactic acidosis.